Valbiotis SAS (ALVAL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Valbiotis SAS (ALVAL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12352
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Valbiotis SAS (Valbiotis) is a biotechnology company that develops novel solutions to help prevent cardiometabolic diseases, besides nutrition products. It develops solutions to prevent type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity and cardiovascular diseases. The company has three products under development based on the active ingredient TOTUM-63. They include Valedia, indicated in prediabetic stage; VAL-63 NAFLD, for the treatment of NASH; and VAL-630, for the treatment of NASH and type 2 diabetes. The company’s pipeline products also include Lipidrive for obesity and VAL–070 for dyslipidemia. The company has partnerships with academic centers to develop its products, besides financial support from the European Union. Valbiotis is headquartered in La Rochelle, France.

Valbiotis SAS (ALVAL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Valbiotis SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Valbiotis SAS, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Valbiotis Raises USD2.45 Million in Second Round Financing 10
Valbiotis Raises USD1.6 Million in Venture Financing 11
Partnerships 12
Valbiotis Enters into Agreement with Biofortis 12
Valbiotis Enters into Agreement with Catholic University of Louvain 13
Valbiotis, Blaise Pascal University and Laboratoire AME2P Enter into Research Agreement 14
Licensing Agreements 15
Valbiotis Enters into Option for Licensing Agreement with SATT Grand Centre 15
Equity Offering 16
Valbiotis Completes Underwriter Partial Exercise of Over-Allotment Option of IPO for USD13.7 Million 16
Valbiotis SAS – Key Competitors 17
Valbiotis SAS – Key Employees 18
Valbiotis SAS – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Strategy And Business Planning 20
Sep 06, 2017: VALBIOTIS Opens a New Clinical Investigation Center at the Institut Pasteur in Lille as Part of the Phase IIa study on Totum-63, the Active Ingredient of Valedia 20
Financial Announcements 21
Sep 29, 2017: VALBIOTIS: First Half of 2017 21
Corporate Communications 24
Oct 08, 2018: Valbiotis confirms its international expansion with the appointment of Murielle Cazaubiel, founder and former executive director of Biofortis Merieux Nutrisciences Europe 24
Aug 30, 2018: VALBOTIS strengthens its board of directors and announces the appointment of Pascal SIRVENT 26
Sep 20, 2017: International Pharmaceutical and Nutrition Expert Dr. Jean Zetlaoui Joins VALBIOTIS’ Supervisory Board 27
Product News 28
Dec 04, 2017: Metformin + TOTUM-63 combination: VALBIOTIS announces first preclinical data for possible use in diabetes real life practice 28
Dec 04, 2017: Metformin + TOTUM-63 Combination: VALBIOTIS Announces First Preclinical Data for Possible Use in Diabetes Real Life Practice 29
Mar 06, 2018: VALBIOTIS: LpD64 acts on alterations of the microbiota involved in the development of obesity 30
Feb 27, 2018: VALBIOTIS completes Phase I/II clinical study recruitment for VAL-070, a product to reduce a cardiovascular risk factor 31
Other Significant Developments 32
Sep 18, 2018: VALBIOTIS expands its innovation capacity with its new Discovery and Preclinical Research platform 32
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Valbiotis SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Valbiotis SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Valbiotis SAS, Deals By Therapy Area, 2012 to YTD 2018 8
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Valbiotis Raises USD2.45 Million in Second Round Financing 10
Valbiotis Raises USD1.6 Million in Venture Financing 11
Valbiotis Enters into Agreement with Biofortis 12
Valbiotis Enters into Agreement with Catholic University of Louvain 13
Valbiotis, Blaise Pascal University and Laboratoire AME2P Enter into Research Agreement 14
Valbiotis Enters into Option for Licensing Agreement with SATT Grand Centre 15
Valbiotis Completes Underwriter Partial Exercise of Over-Allotment Option of IPO for USD13.7 Million 16
Valbiotis SAS, Key Competitors 17
Valbiotis SAS, Key Employees 18

List of Figures
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Valbiotis SAS (ALVAL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pfizer Ltd India (PFIZER):企業の財務・戦略的SWOT分析
    Summary Pfizer Ltd India (Pfizer India) a subsidiary of Pfizer Inc, operates as a pharmaceutical company that develops medicines for brain disorders. The company’s products portfolio comprises of anti-allergics, anti-diabetics, anti-histamines, anti-infectives, anti-parasitics, drugs for cardiovascu …
  • Woori Bank:戦略・SWOT・企業財務分析
    Woori Bank - Strategy, SWOT and Corporate Finance Report Summary Woori Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • China Mobile Limited:戦略・SWOT・企業財務分析
    China Mobile Limited - Strategy, SWOT and Corporate Finance Report Summary China Mobile Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Beneo GmbH:企業の戦略・SWOT・財務情報
    Beneo GmbH - Strategy, SWOT and Corporate Finance Report Summary Beneo GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • East Japan Railway Co:戦略・SWOT・企業財務分析
    East Japan Railway Co - Strategy, SWOT and Corporate Finance Report Summary East Japan Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Albemarle Corporation:企業の戦略・SWOT・財務分析
    Albemarle Corporation - Strategy, SWOT and Corporate Finance Report Summary Albemarle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Alliance Pharma Plc (APH):製薬・医療:M&Aディール及び事業提携情報
    Summary Alliance Pharma Plc (Alliance) is a specialty pharmaceutical company. It focuses on acquisition, licensing, registration and marketing of pharmaceutical products. It promotes acquired and licensed prescription products across various therapeutic categories such as dermatology, central nervou …
  • BioDot Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioDot Inc (BioDot) is a non-contact and quantitative fluid dispensing system manufacturer. The company’s application comprises rapid test, cytogenetics and life science. It provides lateral flow, immunoblots, dry chemistry, low volume PCR, bio chips, biosensors, fish, karyotyping and LIS in …
  • Martifer SGPS SA (MAR):企業の財務・戦略的SWOT分析
    Martifer SGPS SA (MAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Senzime AB (SEZI):医療機器:M&Aディール及び事業提携情報
    Summary Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company's product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients …
  • Millendo Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Millendo Therapeutics Inc (Millendo Therapeutics), formerly Atterocor Inc is a drug development company that develops treatments for endocrine diseases including vasomotor. The company provides development of innovative treatments for orphan endocrine disorders such as adrenocortical carcino …
  • Ferguson Plc:企業のM&A・事業提携・投資動向
    Ferguson Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ferguson Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • British Columbia Investment Management Corp:企業の戦略的SWOT分析
    British Columbia Investment Management Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Hong Kong Polytechnic University:製薬・医療:M&Aディール及び事業提携情報
    Summary Hong Kong Polytechnic University (HKPU) is an educational university that provides research, training and professional education services. The university offers undergraduate, postgraduate, and doctoral level programs; joint research, academic program collaboration, research programs, confer …
  • Immucor, Inc.:医療機器:M&Aディール及び事業提携情報
    Summary Immucor, Inc. (Immucor) is an in-vitro diagnostics company, which specializes in the area of pre-transfusion diagnostics. It carries out the development, production and sale of a comprehensive line of reagents and automated systems. The company’s products are used in performing the tests to …
  • LSB Industries Inc (LXU):企業の財務・戦略的SWOT分析
    LSB Industries Inc (LXU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Commerce Resources Corp (CCE):企業の財務・戦略的SWOT分析
    Summary Commerce Resources Corp (Commerce Resources) is a minerals exploration and development company that explores for deposits of rare earth elements and rare metals. The company acquires, explores, produces, develops, evaluates mineral resource properties, and others. It explores for niobium and …
  • Reliance Industries Limited:企業の戦略・SWOT・財務分析
    Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Shinva Medical Instrument Co Ltd (600587)-医療機器分野:企業M&A・提携分析
    Summary Shinva Medical Instrument Co., Ltd. (Shinva Medical) manufactures and markets medical instruments and environmental protection equipment for various healthcare markets. The company’s products portfolio includes sterilizers, radiotherapy equipment, digital diagnosis equipment, surgical instru …
  • Serica Energy Plc:企業のM&A・事業提携・投資動向
    Serica Energy Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Serica Energy Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆